drugset / Trial / NCT02160574

Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA

NCT02160574

Phase 1 Completed 40 enrolled Zurex Pharma, Inc.
NaSingle-groupDouble-blind

Summary

This is a safety study to determine the cumulative skin irritation potential of ZuraPrep™ and ZuraPrep™ without Isopropyl Alcohol after repetitive patch applications to skin of human subjects.

Timeline

Start
2014-06
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Chlorhexidine Small molecule 2 %
Comparator Chlorhexidine Small molecule 70 %
Comparator Sodium Lauryl Sulfate Small molecule 0.1 %

Indications

No indication recorded.